PodcastThe Directors The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient livesIn a time of uncertainty, “react to the knowns, not the fear” May 16, 2025Vol.51 No.19By Katie Goldberg
Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reducedNCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.” May 16, 2025Vol.51 No.19By Jacquelyn Cobb
Guest Editorial An opportunity for Trump: Position U.S. cancer science to lead the world May 16, 2025Vol.51 No.19By Wafik S. El-Deiry
Trump administration is removing the mainstays of NCI and the federal government’s cancer programPeer review, registries, and evidence-based patient information take a big hit May 09, 2025Vol.51 No.18By Paul Goldberg and Jacquelyn Cobb
Cancer Policy $180M in NCI grants have been terminated by Trump administration, systematic review finds May 09, 2025Vol.51 No.18By Jacquelyn Cobb
Clinical Roundup Incidence rates of some cancer types have risen in people under age 50, NCI study shows May 09, 2025Vol.51 No.18
News Analysis NIH eliminates the NCI Board of Scientific AdvisorsOver its 28 year history, BSA shaped NCI-funded extramural science May 02, 2025Vol.51 No.17By Paul Goldberg
Bertagnolli: NIH funding cuts are “unprecedented and harmful”AACR panel challenges scientists to find stability in a period of “ventricular tachycardia” May 02, 2025Vol.51 No.17By Claire Marie Porter
Cancer Policy HHS ordered to cut 35% of spending on contracts May 02, 2025Vol.51 No.17By Jacquelyn Cobb
In Brief David Ryan named president of Mass General Brigham Cancer Institute May 02, 2025Vol.51 No.17
